Skip to main content
SpringerLink
Log in

O’Dell reloaded

Setzen wir TNF-Inhibitoren zu schnell ein?

O’Dell reloaded

Do we use TNF inhibitors too early?

  • Hot Topics
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Van Vollenhoven RF, Geborek P, Forslind K et al (2012) Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379:1712–1720

    Article  CAS  Google Scholar 

  2. Moreland LW, O’Dell JR, Paulus HE et al (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early Aggressive Rheumatoid Arthritis. Arthritis Rheum 64:2824–2835

    Article  PubMed  CAS  Google Scholar 

  3. Heimans L, Wevers-de Boer KVC, Visser K et al (2013) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis (10.1136/annrheumdis-2013-203243)

  4. O’Dell JR, Mikuls TR, Taylor TH et al (2013) Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. doi:10.1056/NEJMoa1303006

  5. Anonym (2013) Therapiekritik: Rheumatoide Arthritis versus klassische DMARDs. arznei-telegramm 44, Nr.7, 5.7.2013, 60–61

  6. Krüger K, Wollenhaupt J, Albrecht K et al (2012) S1-Leitlinie der DGRh zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis 2012. Z Rheumatol 71:592–603

    Article  PubMed  CAS  Google Scholar 

  7. Kerndokumentation der Rheumazentren 2011, nicht publizierte Daten, DRKZ 2013

  8. Smolen JS, Landewé R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  9. Rantalaiho V, Kautiainen H, Virta L et al (2011) Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000–2007. Scand J Rheumatol 40:16–21

    Article  PubMed  CAS  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. K. Krüger weist auf folgende Beziehungen hin: Der Autor hat Beratungs- oder Vortragshonorare von folgenden Firmen erhalten: Abbvie, Berlin-Chemie, BMS, Medac, MSD, Mundipharma, Pfizer, Roche, UCB.

Author information

Authors and Affiliations

  1. Rheumatologisches Praxiszentrum St.Bonifatius, St.Bonifatius Str. 5, 81541, München, Deutschland

    K. Krüger

Authors
  1. K. Krüger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Krüger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krüger, K. O’Dell reloaded. Z. Rheumatol. 73, 111–112 (2014). https://doi.org/10.1007/s00393-013-1269-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-013-1269-8

Search

Navigation